Akers Biosciences, Inc. 'ABI' or the 'Company' Receipt of Further United States Military Contracts

THOROFARE, N.J., Sept. 17 Akers Biosciences,Inc. (LSE: AKR) which develops, manufactures, and supplies rapid, point ofcare screening and testing products, is pleased to announce that it hasreceived an order from the United States Army for the purchase of itsBreathScan alcohol safety units. This contract is valued at $2,500,000 and isdeliverable beginning immediately.

The Company has previously stated that it had expected significant ordersfrom several departments of the United States Government as a result of its'efforts to increase safety awareness. ABI continues to anticipate such furtherorders in the near future. The units provided consist of the Company's unique,patented disposable breathalyzer device housed within its patented, portableand refillable key ring case.

Thomas A. Nicolette, President and CFO of ABI, commented, "This latestorder will take the total number of our BreathScan alcohol safety units in useby the US Military to over 950,000. This is the beginning of a recurringrevenue business model generated from this product line, where the alcoholbreathalyzers will continually require replacement as they are used anddisposed of. We confidently expect other divisions of the United StatesMilitary to introduce our product line over the course of the very nearfuture.

This is the clearest progressive step to date in transforming ABI from apurely research and development company to business that is capitalizing onits proprietary product lines and generating sustainable revenues from them."

Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, pointof care screening and testing products designed to bring healthcareinformation both rapidly and directly to the patient or healthcare provider.The Company has advanced the science of diagnostics while responding to majorshifts in healthcare through the development of several proprietary platformtechnologies. The company's state-of-the-art rapid diagnostic assays can beperformed virtually anywhere in minutes when time is of the essence. Akers hasaligned with major healthcare companies and high volume medical productsdistributors to maximize product offerings, and to be a major worldwidecompetitor in diagnostics. Additional information on the Company and itsproducts can be found at www.akersbiosciences.com.Contact: Akers Biosciences, Inc. Thomas A. Nicolette, President & CFO Tel (856) 848-8698

SOURCE Akers Biosciences, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...